2m 2m 2m 2m 2m 2m 2m
TAKEDA PHARM SP ADR (TAK)
NYSE
$15.83-$0.02 (-0.09%)
Price as of Jun 23, 2026 6:57 PM EDT- $48.9BMarket Cap
- 7.41%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
TAKEDA PHARM SP ADR (TAK)
$15.83-$0.02 (-0.09%)
Annual
Quarterly
03/31/2026 | 03/31/2025 | 03/31/2024 | 03/31/2023 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 4.5T -1.66% | 4.6T +7.45% | 4.3T +5.87% | 4.0T +12.85% | |
Cost of Revenue | 1.6T -0.55% | 1.6T +10.76% | 1.4T +14.68% | 1.2T +12.40% | |
Gross Profit | 2.9T -2.24% | 3.0T +5.79% | 2.8T +1.93% | 2.8T +13.05% | |
Sales and Marketing Expense | 33.0M -2.94% | 34.0M N/A | 0 +100.00% | -75.0M +120.59% | |
Research and Development Expense | -675.9B -7.44% | -730.2B +0.04% | -729.9B -215.25% | 633.3B +20.38% | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Operating Expenses | 33.0M -2.94% | 34.0M N/A | 0 +100.00% | -75.0M +120.59% | |
Operating Profit | 6.2B -98.19% | 342.6B +60.03% | 214.1B -56.36% | 490.5B +6.44% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -148.1B +7.87% | -137.3B +14.87% | -119.5B +2.19% | -117.0B -4.46% | |
Interest Income and Expense and Net | -148.1B +7.87% | -137.3B +14.87% | -119.5B -202.19% | 117.0B -4.46% | |
Total Nonoperating Income and Expense | 148.1B +7.87% | 137.3B +14.87% | 119.5B +2.19% | 117.0B -4.46% | |
Income before Taxes | -152.1B -240.67% | 108.1B -25.00% | 144.2B -54.52% | 317.0B +37.74% | |
Income Taxes | 9.8B -85.41% | 66.9B +173.23% | -91.4B -257.46% | 58.1B -19.82% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -152.1B -240.67% | 108.1B -25.00% | 144.2B -54.52% | 317.0B +37.74% | |
Net Income from Continuing Operations Applicable to Common | -152.1B -240.67% | 108.1B -25.00% | 144.2B -54.52% | 317.0B +37.74% | |
Basic EPS and Net Income | -96.75 -241.53% | 68.36 -25.77% | 92.09 -54.92% | 204.29 +38.84% | |
Diluted EPS and Net Income | -96.75 -243.91% | 67.23 -26.25% | 91.16 -55.38% | 204.29 +38.84% | |
Basic Weighted Average Shares | 1.6B -0.24% | 1.6B +0.92% | 1.6B +0.81% | 1.6B -0.75% | |
Diluted Weighted Average Shares | 1.6B -0.24% | 1.6B +0.92% | 1.6B +0.81% | 1.6B -0.75% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 595.1B +54.51% | 385.1B -15.88% | 457.8B -14.19% | 533.5B -37.21% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 595.1B +54.51% | 385.1B -15.88% | 457.8B -14.19% | 533.5B -37.21% | |
Total Current Assets | 3.1T +22.58% | 2.5T -1.46% | 2.6T +6.70% | 2.4T -7.54% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | 1.7T +6.85% | |
Total Long-Term Assets | 12.4T +5.92% | 11.7T -6.56% | 12.6T +8.57% | 11.6T +9.22% | |
Total Assets | 15.5T +8.87% | 14.2T -5.70% | 15.1T +8.25% | 14.0T +5.92% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 2.8T +12.99% | 2.5T +8.36% | 2.3T -6.80% | 2.5T +15.67% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 5.2T +9.22% | 4.8T -12.96% | 5.5T +7.82% | 5.1T -4.26% | |
Total Liabilities | 8.1T +10.51% | 7.3T -6.67% | 7.8T +3.05% | 7.6T +1.45% | |
Retained Earnings | 712.4B -40.01% | 1.2T -14.64% | 1.4T -9.73% | 1.5T +4.15% | |
Total Stockholders Equity | 7.4T +7.13% | 6.9T -4.65% | 7.3T +14.47% | 6.4T +11.81% | |
Total Shares Outstanding | 1.6B +0.02% | 1.6B +0.54% | 1.6B N/A | N/A N/A | |
Cash Flow | |||||
Cash from Operating Activities | 1.0T -1.49% | 1.1T +47.58% | 716.3B -26.69% | 977.2B -13.00% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -369.1B +0.57% | -367.1B -20.87% | -463.9B -23.59% | -607.1B +206.42% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -496.8B -33.88% | -751.4B +112.02% | -354.4B -50.02% | -709.1B -33.74% | |
Financials Ratio | |||||
Gross Margin | 65.12% -0.59% | 65.51% -1.55% | 66.54% -3.72% | 69.11% +0.18% | |
Operating Margin | 0.14% -98.15% | 7.48% +48.93% | 5.02% -58.77% | 12.18% -5.68% | |
Return on Assets | -1.02% -238.78% | 0.74% -25.75% | 0.99% -57.54% | 2.34% +32.44% | |
Return on Equity | -2.12% -239.14% | 1.52% -28.07% | 2.12% -59.82% | 5.27% +24.27% | |
Revenue Growth | -1.66% -122.21% | 7.45% +27.04% | 5.87% -54.33% | 12.85% +10.67% | |
Current Ratio | 1.09 +8.49% | 1.01 -9.06% | 1.11 +14.48% | 0.97 -20.06% | |
Cash Ratio | 0.21 +36.78% | 0.15 -22.39% | 0.20 -7.95% | 0.22 -45.71% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow